Shares of Alere Inc (NYSE:ALR) jumped 2.83% to reach at $38.50 during the course of session. The company has experienced volume of 3.01M shares while on average the company has a capacity of trading 1.31M shares.

Alere Inc (NYSE:ALR) on August 8, 2016 announced that it has filed its Form 10-K and reported its financial results for the fourth quarter and full year ended December 31, 2015.

Fourth Quarter 2015 Results

Revenue for the fourth quarter of 2015 was $623 million, a 6.6% decrease compared to $667 million in the fourth quarter of 2014, primarily due to the negative impact of $26 million in foreign currency exchange, a $7 million decrease in pain management revenue, and lower revenues related to our BBI business which was divested in November 2015. Organic growth during the fourth quarter of 2015 was approximately flat compared to the prior year period.

Net income (loss) from continuing operations during the fourth quarter of 2015 was $(19) million, or $(0.28) per diluted share, compared to $(31) million, or $(0.43) per diluted share in the prior year period. During the fourth quarter of 2015, the Company recorded $43 million in pre-tax expenses ($30 million after tax) related to its previously announced voluntary INRatio market withdrawal. On a non-GAAP basis, the Company reported Non-GAAP adjusted EBITDA of $95 million in the fourth quarter of 2015, compared to $127 million in the prior year period.

Full Year 2015 Results

During 2015 Alere made solid progress on its strategic initiatives, returning to organic growth in each of its core businesses, excluding pain management. The Company reported a 4.3% decrease in revenue in 2015, primarily due to the negative impact of $121 million in foreign currency exchange, and organic growth of approximately 1.5% in 2015. The Company launched numerous innovations around the world, including the introduction of two ground-breaking molecular diagnostics platforms in Infectious Disease. Alere i placements reached nearly 4,000 by year end 2015 and Alere q achieved numerous regulatory approvals, including World Health Organization prequalification in June 2016, making it available for public sector procurement.

Alere Inc (NYSE:ALR) holds the market capitalization of $3.36B along with 86.26M outstanding shares. The stock traded in the price range of $37.77 – $40.68 for the last trading session. For the stock, price target value has been calculated at $53.25 based on calls of 4 experts. Stock’s minimum price target estimates has been figured out at $45.00 while the maximum price target forecast is established at $56.00.

As of current trade, Alere Inc (NYSE:ALR) has shown weekly upbeat performance of 4.14%. Its six months performance indicated a bearish movement while its yearly performance reflected a negative trend of -22.61%. Year-to-date (YTD) performance of the stock illustrate downbeat trend of -1.51%. Shares of Alere Inc (NYSE:ALR) currently have an ABR of 2.00, derived from a total of 4 opinions. The company’s price sits -6.39% below from its 50-day moving average of $4.39 and -12.26% below from the stock’s 200-day moving average of $2.97. The company has Relative Strength Index (RSI 14) of 46.45 along with Average True Range (ATR 14) of 2.08. Its weekly and monthly volatility is 3.28%, 5.36% respectively. The company’s beta value is at 1.32.

Alere Inc (NYSE:ALR)’s price to sales ratio for trailing twelve months is 1.32 and price to book ratio for most recent quarter is 2.22, whereas price to cash per share for the most recent quarter is 6.90. Alere Inc (NYSE:ALR)’s price to free cash flow for trailing twelve months is 57.21. Its quick ratio for most recent quarter is 1.40 along with current ratio for most recent quarter of 1.70. Total debt to equity ratio of the company for most recent quarter is 2.42 whereas long term debt to equity ratio for most recent quarter is 2.01. Alere Inc (NYSE:ALR) has a Return on Assets of 5.00%. The company currently has a Return on Equity of 22.40% and Return on Investment of 0.30%.